Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Arrhythmias

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 83 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  2. POKORNEY SD, Kim S, Thomas L, Fonarow GC, et al
    Cardioversion and subsequent quality of life and natural history of atrial fibrillation.
    Am Heart J. 2017;185:59-66.
    PubMed     Text format     Abstract available


  3. ROBINSON VM, Bharucha DB, Mahaffey KW, Dorian P, et al
    Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Am Heart J. 2017;185:43-51.
    PubMed     Text format     Abstract available


  4. WESTENBRINK BD, Alings M, Granger CB, Alexander JH, et al
    Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2017;185:140-149.
    PubMed     Text format     Abstract available


    February 2017
  5. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


    January 2017
  6. RAHMAN F, Himali JJ, Yin X, Beiser AS, et al
    Serum brain-derived neurotrophic factor and risk of atrial fibrillation.
    Am Heart J. 2017;183:69-73.
    PubMed     Text format     Abstract available


  7. DUDINK E, Essers B, Holvoet W, Weijs B, et al
    Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial.
    Am Heart J. 2017;183:49-53.
    PubMed     Text format     Abstract available


  8. OSMANCIK P, Tousek P, Herman D, Neuzil P, et al
    Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study).
    Am Heart J. 2017;183:108-114.
    PubMed     Text format     Abstract available


    December 2016
  9. RANDOLPH TC, Simon DN, Thomas L, Allen LA, et al
    Patient factors associated with quality of life in atrial fibrillation.
    Am Heart J. 2016;182:135-143.
    PubMed     Text format     Abstract available


    November 2016
  10. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  11. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


  12. STEINBERG BA, Shrader P, Kim S, Thomas L, et al
    How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2016;181:145-152.
    PubMed     Text format     Abstract available


  13. RISOM SS, Zwisler AD, Rasmussen TB, Sibilitz KL, et al
    Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: Results of the randomized CopenHeartRFA trial.
    Am Heart J. 2016;181:120-129.
    PubMed     Text format     Abstract available


    October 2016
  14. VAN DER MEERSCH H, De Bacquer D, De Vriese AS
    Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Am Heart J. 2016;184:37-46.
    PubMed     Text format     Abstract available


    September 2016
  15. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Text format     Abstract available


  16. CAIRNS JA
    Oral anticoagulant prescription for atrial fibrillation in the Veterans Administration Health System: National and international differences.
    Am Heart J. 2016;179:184-5.
    PubMed     Text format    


  17. THUNE JJ, Pehrson S, Nielsen JC, Haarbo J, et al
    Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH).
    Am Heart J. 2016;179:136-41.
    PubMed     Text format     Abstract available


  18. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Text format     Abstract available


  19. EZEKOWITZ MD, Pollack CV, Sanders P, Halperin JL, et al
    Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
    Am Heart J. 2016;179:59-68.
    PubMed     Text format     Abstract available


    August 2016
  20. MARTINS RP, Galand V, Colette E, Behar N, et al
    Defining nonvalvular atrial fibrillation: A quest for clarification.
    Am Heart J. 2016;178:161-7.
    PubMed     Text format     Abstract available


  21. LIP GY, Hammerstingl C, Marin F, Cappato R, et al
    Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
    Am Heart J. 2016;178:126-34.
    PubMed     Text format     Abstract available


  22. TABBALAT RA, Hamad NM, Alhaddad IA, Hammoudeh A, et al
    Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial.
    Am Heart J. 2016;178:102-7.
    PubMed     Text format     Abstract available


  23. VEMULAPALLI S, Hellkamp AS, Jones WS, Piccini JP, et al
    Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
    Am Heart J. 2016;178:74-84.
    PubMed     Text format     Abstract available


  24. CHRISTOPHERSEN IE, Yin X, Larson MG, Lubitz SA, et al
    A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study.
    Am Heart J. 2016;178:45-54.
    PubMed     Text format     Abstract available


    July 2016
  25. KIM EJ, Yin X, Fontes JD, Magnani JW, et al
    Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).
    Am Heart J. 2016;177:138-44.
    PubMed     Text format     Abstract available


    June 2016
  26. RAO MP, Ciobanu AO, Lopes RD, Fox KA, et al
    A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale.
    Am Heart J. 2016;176:107-13.
    PubMed     Text format     Abstract available


  27. SCHNABEL RB, Maas R, Wang N, Yin X, et al
    Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.
    Am Heart J. 2016;176:100-6.
    PubMed     Text format     Abstract available


  28. RODRIGUEZ F, Stefanick ML, Greenland P, Soliman EZ, et al
    Racial and ethnic differences in atrial fibrillation risk factors and predictors in women: Findings from the Women's Health Initiative.
    Am Heart J. 2016;176:70-7.
    PubMed     Text format     Abstract available


  29. ECKMAN MH, Lip GY, Wise RE, Speer B, et al
    Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation.
    Am Heart J. 2016;176:17-27.
    PubMed     Text format     Abstract available


  30. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    PubMed     Text format     Abstract available


    May 2016
  31. DE CATERINA R, Andersson U, Alexander JH, Al-Khatib SM, et al
    History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Am Heart J. 2016;175:175-83.
    PubMed     Text format     Abstract available


  32. GOODMAN SG
    Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?
    Am Heart J. 2016;175:168-71.
    PubMed     Text format    


  33. STEINHUBL SR, Mehta RR, Ebner GS, Ballesteros MM, et al
    Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.
    Am Heart J. 2016;175:77-85.
    PubMed     Text format     Abstract available


  34. GUNDLUND A, Fosbol EL, Kim S, Fonarow GC, et al
    Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Am Heart J. 2016;175:28-35.
    PubMed     Text format     Abstract available


  35. ROBERTS JD, Dewland TA, Glidden DV, Hoffmann TJ, et al
    Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.
    Am Heart J. 2016;175:9-17.
    PubMed     Text format     Abstract available


    April 2016
  36. DE VRIESE AS, Caluwe R, Raggi P
    The atrial fibrillation conundrum in dialysis patients.
    Am Heart J. 2016;174:111-9.
    PubMed     Text format     Abstract available


  37. GOLWALA H, Jackson LR 2nd, Simon DN, Piccini JP, et al
    Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
    Am Heart J. 2016;174:29-36.
    PubMed     Text format     Abstract available


    March 2016
  38. TRAN C, Bennell MC, Qiu F, Ko DT, et al
    Predictors and clinical outcomes of inpatient versus ambulatory management after an emergency department visit for atrial fibrillation: A population-based study.
    Am Heart J. 2016;173:161-9.
    PubMed     Text format     Abstract available


  39. MCALISTER FA, Rowe BH
    Variations in the emergency department management of atrial fibrillation: Lessons to be learned.
    Am Heart J. 2016;173:159-60.
    PubMed     Text format    


  40. ZIFF OJ, Camm AJ
    Individualized approaches to thromboprophylaxis in atrial fibrillation.
    Am Heart J. 2016;173:143-58.
    PubMed     Text format     Abstract available


  41. BERKOVITCH A, Kivity S, Klempfner R, Segev S, et al
    Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults.
    Am Heart J. 2016;173:41-8.
    PubMed     Text format     Abstract available


  42. ESSEBAG V, Healey JS, Ayala-Paredes F, Kalfon E, et al
    Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
    Am Heart J. 2016;173:102-7.
    PubMed     Text format     Abstract available


    February 2016
  43. EISEN A, Giugliano RP, Ruff CT, Nordio F, et al
    Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myoc
    Am Heart J. 2016;172:144-51.
    PubMed     Text format     Abstract available


  44. HOEKSTRA M, Hessels L, Rienstra M, Yeh L, et al
    Computer-guided normal-low versus normal-high potassium control after cardiac surgery: No impact on atrial fibrillation or atrial flutter.
    Am Heart J. 2016;172:45-52.
    PubMed     Text format     Abstract available


  45. HAEUSLER KG, Kirchhof P, Heuschmann PU, Laufs U, et al
    Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study.
    Am Heart J. 2016;172:19-25.
    PubMed     Text format     Abstract available


    January 2016
  46. AL-HIJJI MA, Deshmukh AJ, Yao X, Mwangi R, et al
    Trends and predictors of repeat catheter ablation for atrial fibrillation.
    Am Heart J. 2016;171:48-55.
    PubMed     Text format     Abstract available


  47. POKORNEY SD, Radder C, Schulte PJ, Al-Khatib SM, et al
    High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;171:25-32.
    PubMed     Text format     Abstract available


    December 2015
  48. MEYERS HP, Limkakeng AT Jr, Jaffa EJ, Patel A, et al
    Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting of left bundle branch block: A retrospective case-control study.
    Am Heart J. 2015;170:1255-64.
    PubMed     Text format     Abstract available


  49. CHANDRASEKHAR J, Mastoris I, Baber U, Sartori S, et al
    Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Am Heart J. 2015;170:1234-42.
    PubMed     Text format     Abstract available


  50. LEE RJ, Lakkireddy D, Mittal S, Ellis C, et al
    Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design.
    Am Heart J. 2015;170:1184-94.
    PubMed     Text format     Abstract available


  51. AULIN J, Siegbahn A, Hijazi Z, Ezekowitz MD, et al
    Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Am Heart J. 2015;170:1151-60.
    PubMed     Text format     Abstract available


  52. MAGNUSON EA, Vilain K, Wang K, Li H, et al
    Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Am Heart J. 2015;170:1140-50.
    PubMed     Text format     Abstract available


  53. VAKIL KP, Roukoz H, Tung R, Levy WC, et al
    Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation.
    Am Heart J. 2015;170:1099-104.
    PubMed     Text format     Abstract available


    November 2015
  54. ULLAL AJ, Than CT, Fan J, Schmitt S, et al
    Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study.
    Am Heart J. 2015;170:1033-1041.
    PubMed     Text format     Abstract available


  55. MELDUNI RM, Lee HC, Bailey KR, Miller FA Jr, et al
    Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study.
    Am Heart J. 2015;170:914-22.
    PubMed     Text format     Abstract available


    October 2015
  56. ALONSO A, Bahnson JL, Gaussoin SA, Bertoni AG, et al
    Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial.
    Am Heart J. 2015;170:770-777.
    PubMed     Text format     Abstract available


  57. BANSILAL S, Bloomgarden Z, Halperin JL, Hellkamp AS, et al
    Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fi
    Am Heart J. 2015;170:675-682.
    PubMed     Text format     Abstract available


  58. GELLER BJ, Giugliano RP, Braunwald E, Murphy SA, et al
    Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarc
    Am Heart J. 2015;170:669-74.
    PubMed     Text format     Abstract available


  59. MELDUNI RM, Schaff HV, Bailey KR, Cha SS, et al
    Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: A community-based study.
    Am Heart J. 2015;170:659-68.
    PubMed     Text format     Abstract available


    September 2015
  60. KERTAI MD, Li YJ, Ji Y, Qi W, et al
    Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery.
    Am Heart J. 2015;170:580-590.
    PubMed     Text format     Abstract available


  61. ARONIS KN, Wang N, Phillips CL, Benjamin EJ, et al
    Associations of obesity and body fat distribution with incident atrial fibrillation in the biracial health aging and body composition cohort of older adults.
    Am Heart J. 2015;170:498-505.
    PubMed     Text format     Abstract available


  62. PASTORI D, Pignatelli P, Farcomeni A, Cangemi R, et al
    Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
    Am Heart J. 2015;170:490-497.
    PubMed     Text format     Abstract available


  63. NOSEWORTHY PA, Kapa S, Haas LR, Van Houten H, et al
    Trends and predictors of readmission after catheter ablation for atrial fibrillation, 2009-2013.
    Am Heart J. 2015;170:483-9.
    PubMed     Text format     Abstract available


  64. BLOOMFIELD GS, Temu TM, Akwanalo CO, Chen PS, et al
    Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL).
    Am Heart J. 2015;170:455-464.
    PubMed     Text format     Abstract available


    August 2015
  65. RUSSO AM, Daugherty SL, Masoudi FA, Wang Y, et al
    Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR).
    Am Heart J. 2015;170:330-8.
    PubMed     Text format     Abstract available


  66. HEIDENREICH PA, Tsai V, Curtis J, Wang Y, et al
    A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.
    Am Heart J. 2015;170:281-289.
    PubMed     Text format     Abstract available


  67. ZEITLER EP, Al-Khatib SM
    Primary prevention implantable cardioverter defibrillators in women: More questions than answers.
    Am Heart J. 2015;170:197-9.
    PubMed     Text format    


  68. WIESLANDER B, Nijveldt R, Klem I, Lokhnygina Y, et al
    Evaluation of Selvester QRS score for use in presence of conduction abnormalities in a broad population.
    Am Heart J. 2015;170:346-52.
    PubMed     Text format     Abstract available


    July 2015
  69. DAMLUJI AA, Al-Damluji MS, Marzouka GR, Coffey JO, et al
    New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial.
    Am Heart J. 2015;170:156-163.
    PubMed     Text format     Abstract available


  70. POKORNEY SD, Simon DN, Thomas L, Fonarow GC, et al
    Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Am Heart J. 2015;170:141-148.
    PubMed     Text format     Abstract available


  71. CRESSMAN AM, Macdonald EM, Yao Z, Austin PC, et al
    Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study.
    Am Heart J. 2015;170:133-140.
    PubMed     Text format     Abstract available


  72. GRABS V, Peres T, Zelger O, Haller B, et al
    Decreased prevalence of cardiac arrhythmias during and after vigorous and prolonged exercise in healthy male marathon runners.
    Am Heart J. 2015;170:149-55.
    PubMed     Text format     Abstract available


  73. ESTES EH, Zhang ZM, Li Y, Tereschenko LG, et al
    The Romhilt-Estes left ventricular hypertrophy score and its components predict all-cause mortality in the general population.
    Am Heart J. 2015;170:104-9.
    PubMed     Text format     Abstract available


  74. HELLER S, Darpo B, Mitchell MI, Linnebjerg H, et al
    Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
    Am Heart J. 2015;170:23-35.
    PubMed     Text format     Abstract available


    June 2015
  75. CHAN PS, Krumholz HM, Spertus JA, Curtis LH, et al
    Effectiveness of implantable cardioverter-defibrillators in survivors of inhospital cardiac arrest.
    Am Heart J. 2015;169:870-878.
    PubMed     Text format     Abstract available


  76. SUGIOKA K, Takagi M, Sakamoto S, Fujita S, et al
    Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study.
    Am Heart J. 2015;169:783-90.
    PubMed     Text format     Abstract available


  77. SINNER MF, Piccini JP, Greiner MA, Walkey AJ, et al
    Geographic variation in the use of catheter ablation for atrial fibrillation among Medicare beneficiaries.
    Am Heart J. 2015;169:775-782.
    PubMed     Text format     Abstract available


    May 2015
  78. ABED HS, Nelson AJ, Richardson JD, Worthley SG, et al
    Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation.
    Am Heart J. 2015;169:655-662.
    PubMed     Text format     Abstract available


  79. HOLMQVIST F, Guan N, Zhu Z, Kowey PR, et al
    Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2015;169:647-654.
    PubMed     Text format     Abstract available


  80. LIP GY, Merino J, Ezekowitz M, Ellenbogen K, et al
    A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2015;169:597-604.
    PubMed     Text format     Abstract available


  81. TUNG P, Zimetbaum P
    Obstructive sleep apnea and atrial fibrillation progression. Another reason to wear continuous positive airway pressure?
    Am Heart J. 2015;169:595-6.
    PubMed     Text format    


  82. MASRI A, Pierson LM, Smedira NG, Agarwal S, et al
    Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography.
    Am Heart J. 2015;169:684-692.
    PubMed     Text format     Abstract available


    April 2015
  83. EARLE NJ, Poppe KK, Pilbrow AP, Cameron VA, et al
    Genetic markers of repolarization and arrhythmic events after acute coronary syndromes.
    Am Heart J. 2015;169:579-586.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: